Barinez

Barinez2 mg

Tablet

Baricitinib

Beacon Pharmaceuticals PLC

Product Code : 1954
MRP 25.00
10% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Barinez 2 mg

Barinez 2 mg is indicated for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of Barinez 2 mg in combination with other JAK inhibitors ... Read moreBarinez 2 mg is indicated for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of Barinez 2 mg in combination with other JAK inhibitors, biologic DMARDs or with potent immunosuppressants such as Azathioprine and cyclosporine is not recommended.

Theropeutic Class

Immunosuppressant

Pharmacology

Barinez 2 mg is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Barinez 2 mg modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

Dosage & Administration of Barinez 2 mg

The recommended dose of Barinez 2 mg is 2 mg once daily. Barinez 2 mg may be used as monotherapy or in combination with Methotrexate or other DMARDs.

Dosage of Barinez 2 mg

Adult dose: The recommended dose of Barinez 2 mg is 2 mg once daily. It may be used as monotherapy or in combination with Methotrexate or other Disease-modifying antirheumatic drugs (DMARDS). Barinez 2 mg can be given orally with or without food.Pediatric Use: The safety and effectiveness of Barinez 2 mg in pediatric patients have not been established.Geriatric Use: Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.Hepatic Impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment.Renal impairment: Barinez 2 mg is not recommended for use in patients with estimated GFR of less than 60 mL/min/I .73 m2.

Interaction of Barinez 2 mg

Strong OAT3 Inhibitors: Barinez 2 mg exposure is increased when it is co-administered with strong OAT3 inhibitors (such as probenecid).Other JAK Inhibitors or Biologic DMARDs: Barinez 2 mg has not been studied in combination with other JAK inhibitors or with biologic DMARDS.

Contraindications

Anemia: Avoid initiation or interrupt Barinez 2 mg in patients with hemoglobin less than 8 g/dL. Lymphopenia: Avoid initiation or interrupt Barinez 2 mg in patients with an Absolute Lymphocyte Count less than 500 cells/mm3. Neutropenia: Avoid initiation or interrupt Barinez 2 mg in patients with an Absolute Neutrophil Count less than 1000 cells/mm3.

Side Effects of Barinez 2 mg

The most commonly reported adverse drug reactions (ADRs) occurring in 2% of patients treated with Barinez 2 mg monotherapy or in combination with conventional synthetic DMARDs were increased LDL cholesterol (33.6%), upper respiratory tract infections (14.7%) and nausea (2.8%).

Pregnancy & Lactation

It is not known if Barinez 2 mg will harm an unborn baby. Because of the potential for serious adverse reactions in nursing infants, advice an Barinez 2 mg treated woman not to breastfeed.

Precautions & Warnings

Serious Infections: Avoid use of Barinez 2 mg in patients with an active, serious infection, including localized infections. Tuberculosis: Barinez 2 mg should not be given to patients with active TB. Malignancy and Lymphoproliferative Disorders: Consider the risks and benefits of Barinez 2 mg treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Barinez 2 mg in patients who develop a malignancy. Thrombosis: Barinez 2 mg should be used with caution in patients who may be at increased risk of thrombosis. Gastrointestinal Perforations: Barinez 2 mg should be used with caution in patients who may be at increased risk for gastrointestinal perforation. To be dispensed only by the prescription of a registered physician.

Overdose Effects of Barinez 2 mg

In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.

Storage Conditions

Store at or below 30°C temperature. Keep away from light and wet place. Keep out of reach of children.

Use In Special Populations

Moderate Renal Impairment: Reduce dose to 1 mg once daily.

Drug Classes

Immunosuppressant

Mode Of Action

Barinez 2 mg is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Barinez 2 mg modulate these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.

Pregnancy

Barinez 2 mg is contraindicated during pregnancy. No information is available on the presence of Barinez 2 mg in human milk.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.